Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation

J Wilson, 1* M Connock, 1 F Song, 1 G Yao, 2 A Fry-Smith, 1 J Raftery 2 and D Peake 3

1 Department of Public and Epidemiology, University of Birmingham, UK
2 Health Economics Facility, Health Services Management Centre, University of Birmingham, UK
3 University Hospitals, Birmingham NHS Trust, Edgbaston, UK

* Corresponding author

Executive summary

Health Technology Assessment 2005; Vol. 9: No. 25
Objectives
The objectives of this study were to assess the clinical and cost-effectiveness of imatinib in the treatment of unresectable and/or metastatic, KIT-positive, gastrointestinal stromal tumours (GISTs), relative to current standard treatments.

Methods
Electronic literature databases and the references of identified studies were searched for relevant studies. The searches were not restricted by language or publication status. Because there were no randomised trials that have directly compared imatinib with the current standard treatment in patients with advanced GIST, this review included non-randomised controlled studies, cohort studies, and case series that reported effectiveness results of treatment with imatinib and/or other interventions in patients with advanced GIST. The effectiveness assessment was based on the comparison of results from imatinib trials and results from studies of historical control patients.

Economic evaluation was based mainly on an assessment and modification (when judged necessary) of a model submitted by Novartis. The results from a new model confirmed the findings from the modified Novartis model.

Effectiveness assessment
Two trials and eight case studies were identified from the published literature, and four ongoing trials and a case series were identified, which have reported data in abstract form only. Evidence from published uncontrolled trials involving 187 patients, and from abstracts reporting similar uncontrolled trials involving 1700 patients, indicate that approximately 50% of imatinib-treated individuals with advanced GIST experience a dramatic clinical response in terms of at least a 50% reduction in tumour mass. At present, although useful data are accumulating, it is not possible to predict which patients may respond in this way. Fifteen studies where possible GIST patients had been treated with therapies other than imatinib or best supportive care were also identified. Because of the problems of diagnosis, in particular, an indirect comparison using these studies was not possible, therefore the results of these studies were not compared to the imatinib trials in the following section.

All imatinib-treated patients experienced adverse effects, although the adverse events were relatively mild.

Overall, imatinib was reported to be well tolerated. The most common serious events included unspecified haemorrhage and neutropenia. Skin rash, oedema and periorbital oedema were the common adverse events observed. Patients on the highest dose regimen (1000 mg per day in one trial) may experience dose-limiting drug toxicity.

A systematic review of prognostic studies confirmed that a large number of patients with advanced GIST die within a few years of diagnosis, but some patients may survive for many years. The evidence from modelling suggested that the patients in the imatinib trial were relatively comparable to all patients with recurrent or metastatic GIST in an unpublished study. (Text related to this study is academic in confidence and has been removed.)

Cost-effectiveness
Novartis submitted an economic evaluation of imatinib for unresectable and/or metastatic GIST. After a structured assessment of the Novartis model, it was found to be clearly presented and well written, the model structure and input data were transparent, and the level of simplification was reasonable in terms of the objectives and data availability. However, the original Novartis model overestimated the cost-effectiveness of imatinib because of disproportion of survival and time-to-treatment failure in the imatinib arm, and the use of a possibly biased survival curve for patients in the control arm.

The original Novartis model was modified so that the two important shortcomings were corrected. The modified Novartis model became less sensitive
to the choice of the survival curve for the control patients. According to the modified Novartis model, the estimated cost per quality-adjusted life-year (QALY) was £85,224 (range £51,515–98,889) after 2 years, £41,219 (£27,331–44,236) after 5 years and £29,789 (£21,404–33,976) after 10 years. The results from a new Birmingham model were also within the range of estimates from the modified Novartis model.

Conclusions

Evidence from uncontrolled studies indicates that the treatment with imatinib brings about clinically significant shrinkage of tumour mass in about half of patients with unresectable and/or metastatic, KIT-positive GIST. Results of modelling based on data from uncontrolled studies suggest that imatinib treatment improves survival in patients with unresectable and/or metastatic GIST. The economic evaluation modelling suggests that the cost per QALY gained ranges from £51,515 to £98,889 after 2 years, from £27,331 to £44,236 after 5 years and from £21,404 to £33,976 after 10 years. The estimates after 2 years are very uncertain because they were based on extrapolation beyond the trial data. The conclusions are based on the existing evidence, and uncontrolled trials in progress will provide additional data from more imatinib-treated patients and/or data of longer follow-up.

Recommendations for research

- More emphasis should be placed on quality of life within trials involving patients with advanced malignancy. Adverse events should be reported so that intertrial comparisons can be made. As indicated by the increase in grade 3 adverse events with longer term use of imatinib reported in the industrial submission, long-term follow-up of adverse events is needed.
- Patients diagnosed with GIST are a heterogeneous group. Subgroup analysis of which, if any, patient types have a better or worse response to imatinib is needed. Analysis of individual patient data may be a good way of exploring these issues.
- There are many uncertainties surrounding imatinib prescription, such as the length of time for which patients should be on imatinib, the dose (i.e. is it better to step up or step down), drug resistance and the optimum time-point in the disease course to give the drug. When the present ongoing trials have had time to mature, answers to some of these uncertainties may be forthcoming and ongoing trials on adjuvant therapy in patients with primary disease may answer the question of timing of imatinib therapy. Secondary research, such as an update of this systematic review and a reassessment of the model, is highly recommended when ongoing trials reach completion.

Publication

The research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’ that is being developed to improve the evidence of clinical practice throughout the NHS.

The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.

The HTA Programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public, service-users groups and professional bodies such as Royal Colleges and NHS Trusts. Research suggestions are carefully considered by panels of independent experts (including service users) whose advice results in a ranked list of recommended research priorities. The HTA Programme then commissions the research team best suited to undertake the work, in the manner most appropriate to find the relevant answers. Some projects may take only months, others need several years to answer the research questions adequately. They may involve synthesising existing evidence or conducting a trial to produce new evidence where none currently exists.

Additionally, through its Technology Assessment Report (TAR) call-off contract, the HTA Programme is able to commission bespoke reports, principally for NICE, but also for other policy customers, such as a National Clinical Director. TARs bring together evidence on key aspects of the use of specific technologies and usually have to be completed within a short time period.

Criteria for inclusion in the HTA monograph series

Reports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in *Health Technology Assessment* are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this monograph was commissioned and funded by the HTA Programme on behalf of NICE as project number 03/01/01. The protocol was agreed in April 2003. The assessment report began editorial review in March 2004 and was accepted for publication in November 2004. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme, NICE or the Department of Health.

Editor-in-Chief: Professor Tom Walley
Series Editors: Dr Peter Davidson, Dr Chris Hyde, Dr Ruairidh Milne, Dr Rob Riemsma and Dr Ken Stein
Managing Editors: Sally Bailey and Sarah Llewellyn Lloyd

ISSN 1366-5278

© Queen’s Printer and Controller of HMSO 2005

This monograph may be freely reproduced for the purposes of private research and study and may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.

Applications for commercial reproduction should be addressed to NCCHTA, Mailpoint 728, Boldrewood, University of Southampton, Southampton, SO16 7PX, UK.

Published by Gray Publishing, Tunbridge Wells, Kent, on behalf of NCCHTA.
Printed on acid-free paper in the UK by St Edmundsbury Press Ltd, Bury St Edmunds, Suffolk.